Intelligence Feed event · Equity · 2026-09-09

    Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook

    Question

    Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook

    Direct answer

    DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-09
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook”, revision 1, evidence through 2026-09-09. https://marketontology.com/market-events/2026-09-09/dentsply-sirona-beats-q2-eps-at-0-52-and-reaffirms-fy26-sales-outlook-e45947

    EQUITY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
    DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.
    XRAY
    Impact
    66
    SEP 9
    SIG
    88%
    XRAY
    Dentsply Sirona Beats Q2 EPS at $0.52 and Reaffirms FY26 Sales Outlook
    DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.
    → Earnings beat of 16 cents against lowered expectations stabilizes XRAY's forward multiple while flat full-year guidance caps intermediate upside.
    Impact
    DENTSPLY SIRONA (XRAY) posted second-quarter adjusted EPS of $0.52, outperforming the $0.36 consensus forecast despite a 4.1% year-over-year decline in overall revenue. Operational strength in the Wellspect Healthcare segment, which expanded 7.1%, helped mitigate dental equipment demand pressure. The company reaffirmed full-year 2026 guidance, targeting net sales between $3.5 billion and $3.6 billion alongside adjusted EPS of $1.40 to $1.50, demonstrating cost discipline amid uneven European and North American dental consumable volumes.
    Affected
    XRAY
    Transmission
    Earnings beat of 16 cents against lowered expectations stabilizes XRAY's forward multiple while flat full-year guidance caps intermediate upside.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    XRAYearnings beat driven by healthcare segment margin preservation against soft dental salesUp1-5dXRAY exceeded Q2 adjusted EPS estimates with 52 cents vs 36 cents consensus and reiterated FY26 guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XRAYUpdisagreed10.72 2026-09-09-2.05%-5.41%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month